In short
A new drug called peresolimab (LY3462817) is being studied in clinical trials for the treatment of moderate to severe rheumatoid arthritis. This drug is a humanized IgG1 monoclonal antibody that targets PD-1, a protein involved in immune system regulation. The ongoing Phase 2b study aims to evaluate the safety and effectiveness of peresolimab compared to a placebo in adults with rheumatoid arthritis.
At a glance
- Drug Name
- Peresolimab (LY3462817)
- Drug Type
- Humanized IgG1 monoclonal antibody against PD-1
- Condition Studied
- Moderate to severe rheumatoid arthritis
- Trial Phase
- Phase 2b
- Main Objective
- Evaluate efficacy in achieving ACR20 compared to placebo
- Administration Method
- Subcutaneous injection
- Maximum Daily Dose
- 36 mg
- Maximum Total Dose
- 15,000 mg
- Maximum Treatment Period
- 60 weeks
- Key Inclusion Criteria
- Adult-onset rheumatoid arthritis for at least 3 months
- Key Exclusion Criteria
- Recent cancer history, certain infections, hepatitis B or C
What is Peresolimab?
Peresolimab, also known by its code name LY3462817, is a new medication being studied for the treatment of rheumatoid arthritis. It is classified as a humanised IgG1 monoclonal antibody that targets a specific protein in the body called PD-1.
To break this down:
- Humanised means the antibody is designed to be similar to human antibodies, reducing the chance of the body rejecting it.
- IgG1 refers to a type of antibody that our immune system naturally produces.
- Monoclonal antibody means it's a laboratory-made protein that can bind to specific substances in the body.
- PD-1 (Programmed Cell Death protein 1) is a protein involved in regulating the immune system.
Target Condition: Rheumatoid Arthritis
Peresolimab is being developed to treat moderate to severe rheumatoid arthritis in adults. Rheumatoid arthritis is an autoimmune disease where the body's immune system mistakenly attacks the joints, causing inflammation, pain, and potentially long-term damage.
How Peresolimab Works
While the exact mechanism isn't fully detailed in the trial information, we can infer that peresolimab likely works by targeting the PD-1 protein. In autoimmune diseases like rheumatoid arthritis, modulating the activity of PD-1 might help regulate the overactive immune response that causes joint inflammation and damage.
Clinical Trial Details
Peresolimab is currently being studied in a Phase 2b clinical trial. This means it's in a relatively early stage of testing in humans, where researchers are trying to determine its effectiveness and safety. The main goal of this study is to see if peresolimab is better than a placebo in helping patients achieve what's called an ACR20 response.
ACR20 is a standard measure used in rheumatoid arthritis trials. It indicates a 20% improvement in the number of tender and swollen joints, along with a 20% improvement in at least three of five other measures of disease activity.
Eligibility Criteria
To participate in this study, patients must meet certain criteria:
Inclusion Criteria:
- Adults diagnosed with rheumatoid arthritis for at least 3 months
Exclusion Criteria:
- History of cancer within the last 5 years (with some exceptions for certain skin cancers and cervical cancer)
- Cervical dysplasia (abnormal cells on the surface of the cervix)
- Certain types of infections within the last 3 months
- Current hepatitis B or C infection
Administration and Dosage
Peresolimab is administered as a solution for infusion, which means it's given directly into the bloodstream through an IV. However, the trial information also mentions subcutaneous injection as a route of administration, suggesting that it might be given as an injection under the skin in some cases.
The maximum daily dose mentioned in the trial is 36 mg, with a maximum total dose of 15,000 mg over a treatment period of up to 60 weeks.
Potential Benefits
If successful, peresolimab could offer a new treatment option for people with moderate to severe rheumatoid arthritis. It might be particularly helpful for patients who haven't responded well to existing treatments. However, it's important to remember that the drug is still in the testing phase, and more research is needed to confirm its safety and effectiveness.